Investment
Features
FeesSafety
Academy
More
Pluang+

Warren Buffett named chairman emeritus of Berkshire Hathaway; son Howard becomes chairman.

Market News
18 Sep 2026
New York Post
View Source
Neutral
Warren Buffett named chairman emeritus of Berkshire Hathaway; son Howard becomes chairman.

Warren Buffett, the legendary investor and former CEO of Berkshire Hathaway, has been named chairman emeritus, effective immediately. His son, Howard Buffett, who has been a director since 1993, is appointed as the new chairman. Buffett will remain on the board, offering his guidance while the company continues under new leadership. This marks a formal transition as Buffett steps back, with his long-time lieutenant Greg Abel now CEO, ensuring the company's culture and values remain intact.

Warren Buffett's leadership transition at Berkshire Hathaway provides context for Pluang's Financials sector data. As of Sep 18, 2026 15:51 WIB, 48 of 74 priced Financials-sector US stocks on Pluang rose while 18 fell. Notable movers include Nomura Holdings Inc at USD 10.09 with a 1-day change of -1.37%, Futu Holdings Ltd at USD 112.50 with a 1-day change of +1.02%, and Bank of New York Mellon Corp at USD 154.54 with a 1-day change of +0.99%.

More News

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
1 hour ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App